Rock Health: $7.4B went into digital health in H1 2026, and 20 rounds took 45%
Rock Health: U.S. digital health startups raised $7.4 billion across 244 deals in H1 2026, up from $6.4 billion on 245 deals in H1 2025. The rebound is concentrated. Nineteen companies raised 20 $100 million-plus rounds that captured 45% of capital.
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Key facts, context, and what it means.
Key takeaways
In H1 2026, 19 companies raised 20 mega-deals of $100 million or more, representing 45% of all capital invested, according to Rock Health.
According to Rock Health, the firm stopped labeling startups as “AI-enabled,” saying the technology is now too widespread for the label to be meaningful.
Free workspace
Turn your Healthcare expertise into content.
Record interviews, organize footage, and write with AI in a free MarketScale workspace. Qualifying companies also get one professional video edit a month. No credit card.
Rock Health counted $7.4 billion invested into U.S. digital health startups across 244 deals in the first half of 2026. Nineteen companies raised 20 rounds of $100 million or more, representing 45% of all capital invested, according to Rock Health’s H1 2026 funding and market overview published July 13.
According to Rock Health, 19 companies secured 20 rounds of $100 million or more in H1 2026, capturing 45% of total digital health venture funding from just over 8% of transactions.
The numbers behind the rebound, and where it’s concentrated
Rock Health’s dataset puts H1 2026 at $7.4 billion, up $1 billion from H1 2025’s $6.4 billion, on roughly the same deal count, 244 deals versus 245. Rock Health also reported a quarterly split of $4.2 billion in Q1 and $3.2 billion in Q2.
The median deal size rose to $14 million in H1 2026 from $12 million in 2025, according to Rock Health.
Fierce Healthcare, reporting on the same Rock Health analysis, noted that the mega deal list included rounds for Whoop ($575 million), OpenEvidence ($250 million), Grow Therapy ($150 million), Verily ($300 million), Talkiatry ($210 million), eMed ($200 million), Forus ($160 million), and Aidoc ($150 million).
According to Rock Health, it discontinued its “AI-enabled” classification because AI is now too widespread for the label to be meaningful.
Where the money is going: mental health and GLP-1 ecosystems
Mental health continues to be the top-funded clinical indication, and weight management and obesity are the second most-funded clinical indication, according to Fierce Healthcare.
What this changes in vendor evaluation in 2026
Rock Health’s own explanation for the funding pattern is that as AI makes more software easier to build, defensible advantage shifts to what is harder to replicate. Rock Health described four themes it sees investors seeking: domain expertise, owning more of the workflow, hands-on delivery, and strong partnerships or network effects.
Rock Health reported $4.2 billion in Q1 and $3.2 billion in Q2 of 2026 digital health venture funding.
Sources
Your experts belong here
Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.
Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.
About the author
The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.
